Hashtag
Men's Weekly

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.

At the conference, Dr. Stamler will be featured on a panel entitled, "New Approaches to Parkinson's and Movement Disorders." He will also present a company update and participate in investor and business development meetings.

The program for the 6th Annual NIF is designed to cover the latest developments in global bio-partnering and investment, with additional panels covering scientific advances in key therapeutic areas of neurodegenerative diseases and CNS more broadly, which includes neuropsychiatry, ophthalmology, neurotech and digital therapeutics.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

 Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-participate-in-the-sachs-associates-6th-annual-neuroscience-innovation-forum-301712033.html

Authors: PR Newswire

Read more https://www.prnasia.com/story/archive/3976287_CN76287_0

Health & Wellness

Disability Care in Melbourne: What Families Need to Know in 2025

Hashtag.net.au - avatar Hashtag.net.au

If you’re supporting a loved one with a disability in Melbourne, you’ll know how important it is to find the right care—and how overwhelming it can be to navigate the system. With the National Disab...

Online Medical Certificate Services: Essential Features to Look Out For

Hashtag.net.au - avatar Hashtag.net.au

"Discover top online medical certificate services! Essential features to look for to get trusted and efficient results." Choosing high-quality services is essential for ensuring reliable, efficient, ...

The Importance of Having a Defibrillator in Public Spaces

Hashtag.net.au - avatar Hashtag.net.au

Life is uncertain! It is almost impossible to be 100% sure of the future, anything can happen to anyone at any time. However, in the case of Sudden Cardiac Arrests (SCA), the presence of an Automat...